TICOVAC Highlights

(tick-borne encephalitis vaccine,whole virus, inactivated)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TICOVAC safely and effectively. See full prescribing information for TICOVAC.

TICOVAC (Tick-Borne Encephalitis Vaccine), Suspension for intramuscular injection
Initial U.S. Approval: 2021

INDICATIONS AND USAGE

TICOVAC is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE). TICOVAC is approved for use in individuals 1 year of age and older. (1)

DOSAGE AND ADMINISTRATION

For intramuscular use only.

•
1 through 15 years of age: each dose 0.25 mL
•
16 years of age and older: each dose 0.5 mL

Primary Vaccination: Three doses (2.1)

Primary Vaccination Schedule

1 through 15 years of age

16 years of age and older

First dose

Day 0

Day 0

Second dose

1 to 3 months after the first vaccination

14 days to 3 months after the first vaccination

Third dose

5 to 12 months after the second vaccination

5 to 12 months after the second vaccination

A booster dose (fourth dose) may be given at least 3 years after completion of the primary immunization series if ongoing exposure or re-exposure to tick-borne encephalitis virus (TBEV) is expected.

DOSAGE FORMS AND STRENGTHS

Suspension for injection supplied as a 0.25 mL or 0.5 mL single-dose in pre-filled syringes. (3)

CONTRAINDICATIONS

•
Severe allergic reaction (e.g. anaphylaxis) to any component of TICOVAC. (4)

ADVERSE REACTIONS

The most common adverse reactions are as follows:

•
1 through 15 years of age: Local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%). (6.1)
•
16 through 65 years of age: Local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or https://vaers.hhs.gov.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 7/2023

Find TICOVAC medical information:

Find TICOVAC medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TICOVAC Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TICOVAC safely and effectively. See full prescribing information for TICOVAC.

TICOVAC (Tick-Borne Encephalitis Vaccine), Suspension for intramuscular injection
Initial U.S. Approval: 2021

INDICATIONS AND USAGE

TICOVAC is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE). TICOVAC is approved for use in individuals 1 year of age and older. (1)

DOSAGE AND ADMINISTRATION

For intramuscular use only.

•
1 through 15 years of age: each dose 0.25 mL
•
16 years of age and older: each dose 0.5 mL

Primary Vaccination: Three doses (2.1)

Primary Vaccination Schedule

1 through 15 years of age

16 years of age and older

First dose

Day 0

Day 0

Second dose

1 to 3 months after the first vaccination

14 days to 3 months after the first vaccination

Third dose

5 to 12 months after the second vaccination

5 to 12 months after the second vaccination

A booster dose (fourth dose) may be given at least 3 years after completion of the primary immunization series if ongoing exposure or re-exposure to tick-borne encephalitis virus (TBEV) is expected.

DOSAGE FORMS AND STRENGTHS

Suspension for injection supplied as a 0.25 mL or 0.5 mL single-dose in pre-filled syringes. (3)

CONTRAINDICATIONS

•
Severe allergic reaction (e.g. anaphylaxis) to any component of TICOVAC. (4)

ADVERSE REACTIONS

The most common adverse reactions are as follows:

•
1 through 15 years of age: Local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%). (6.1)
•
16 through 65 years of age: Local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or https://vaers.hhs.gov.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 7/2023
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.